[HTML][HTML] 2-Oxoglutarate-dependent dioxygenases in cancer

JA Losman, P Koivunen, WG Kaelin Jr - Nature Reviews Cancer, 2020 - nature.com
Oxoglutarate-dependent dioxygenases (2OGDDs) are a superfamily of enzymes that play
diverse roles in many biological processes, including regulation of hypoxia-inducible factor …

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

DA Sallman, A List - Blood, The Journal of the American Society …, 2019 - ashpublications.org
In cancer biology, tumor-promoting inflammation and an inflammatory microenvironment
play a vital role in disease pathogenesis. In the past decade, aberrant innate immune …

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

H Yang, C Bueso-Ramos, C DiNardo, MR Estecio… - Leukemia, 2014 - nature.com
Blockade of immune checkpoints is emerging as a new form of anticancer therapy. We
studied the expression of programmed death ligand 1 (PD-L1), PD-L2, programmed death 1 …

Chronic immune response dysregulation in MDS pathogenesis

L Barreyro, TM Chlon… - Blood, The Journal of …, 2018 - ashpublications.org
Chronic innate immune signaling in hematopoietic cells is widely described in
myelodysplastic syndromes (MDS), and innate immune pathway activation, predominantly …

The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism

S Chang, S Yim, H Park - Experimental & molecular medicine, 2019 - nature.com
Recent studies on mutations in cancer genomes have distinguished driver mutations from
passenger mutations, which occur as byproducts of cancer development. The cancer …

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

X Yang, L Ma, X Zhang, L Huang, J Wei - Experimental Hematology & …, 2022 - Springer
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal
hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately …

[HTML][HTML] Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs

T Muto, CS Walker, K Choi, K Hueneman… - Nature …, 2020 - nature.com
Despite evidence of chronic inflammation in myelodysplastic syndrome (MDS) and cell-
intrinsic dysregulation of Toll-like receptor (TLR) signaling in MDS hematopoietic stem and …

[HTML][HTML] Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9

RK Schneider, M Schenone, MV Ferreira, R Kramann… - Nature medicine, 2016 - nature.com
Impaired erythropoiesis in the deletion 5q (del (5q)) subtype of myelodysplastic syndrome
(MDS) has been linked to heterozygous deletion of RPS14, which encodes the ribosomal …

[HTML][HTML] Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes

N Daver, P Boddu, G Garcia-Manero, SS Yadav… - Leukemia, 2018 - nature.com
Immune checkpoint inhibitors, as single-agent therapy, have shown modest clinical efficacy
in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). As …

Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes

I Gañán-Gómez, Y Wei, DT Starczynowski, S Colla… - Leukemia, 2015 - nature.com
Myelodysplastic syndromes (MDSs) are a group of heterogeneous clonal hematologic
malignancies that are characterized by defective bone marrow (BM) hematopoiesis and by …